HK1022719A1 - Hamster ef-1 alpha transcriptional regulatory DNA - Google Patents

Hamster ef-1 alpha transcriptional regulatory DNA

Info

Publication number
HK1022719A1
HK1022719A1 HK00101582A HK00101582A HK1022719A1 HK 1022719 A1 HK1022719 A1 HK 1022719A1 HK 00101582 A HK00101582 A HK 00101582A HK 00101582 A HK00101582 A HK 00101582A HK 1022719 A1 HK1022719 A1 HK 1022719A1
Authority
HK
Hong Kong
Prior art keywords
regulatory dna
hamster
transcriptional regulatory
alpha transcriptional
expression constructs
Prior art date
Application number
HK00101582A
Other languages
English (en)
Inventor
Daniel S Allison
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of HK1022719A1 publication Critical patent/HK1022719A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK00101582A 1997-05-01 2000-03-15 Hamster ef-1 alpha transcriptional regulatory DNA HK1022719A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/847,218 US5888809A (en) 1997-05-01 1997-05-01 Hamster EF-1α transcriptional regulatory DNA
PCT/US1998/008906 WO1998049289A1 (en) 1997-05-01 1998-05-01 HAMSTER EF-1α TRANSCRIPTIONAL REGULATORY DNA

Publications (1)

Publication Number Publication Date
HK1022719A1 true HK1022719A1 (en) 2000-08-18

Family

ID=25300098

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101582A HK1022719A1 (en) 1997-05-01 2000-03-15 Hamster ef-1 alpha transcriptional regulatory DNA

Country Status (20)

Country Link
US (1) US5888809A (de)
EP (2) EP1676916A1 (de)
JP (1) JP2000513948A (de)
CN (2) CN100430477C (de)
AT (1) ATE318900T1 (de)
AU (1) AU742561B2 (de)
BR (1) BR9804896B1 (de)
CZ (1) CZ296544B6 (de)
DE (1) DE69833649T2 (de)
DK (1) DK0920498T3 (de)
ES (1) ES2263206T3 (de)
HK (1) HK1022719A1 (de)
HU (1) HU225764B1 (de)
IL (1) IL127897A (de)
NO (1) NO323853B1 (de)
PL (1) PL195604B1 (de)
PT (1) PT920498E (de)
RU (2) RU2249617C2 (de)
SK (1) SK285664B6 (de)
WO (1) WO1998049289A1 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
KR20000046969A (ko) * 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
AU2002213196A1 (en) * 2000-10-12 2002-04-22 Icos Corporation Modulation of ligand binding/enzymatic activity of alpha beta proteins
WO2002050264A2 (en) * 2000-12-18 2002-06-27 Wyeth Promoters and recombinant expression constructs
JP4500044B2 (ja) * 2001-07-04 2010-07-14 クロマジェニックス ビー．ブイ． 遺伝子転写を調節する特性を含むｄｎａ配列及びそのようなｄｎａ配列を検出し且つ使用するための方法
AU2003243059A1 (en) * 2002-06-14 2003-12-31 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
CA2722998C (en) * 2002-06-14 2014-12-02 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
CA2510179C (en) * 2002-12-18 2013-04-23 Chromagenics B.V. A method for improving protein production
EP1572994B1 (de) * 2002-12-20 2007-02-21 Chromagenics B.V. Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
EP2380985B1 (de) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Vitamin-K-Epoxid-Reduktase exprimierende Zellen und deren Verwendung
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
NZ553700A (en) * 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
US20060195935A1 (en) * 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
CA2581422C (en) * 2004-11-08 2012-05-22 Chromagenics B.V. Selection of host cells expressing protein at high levels
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20090325226A1 (en) * 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
KR101030612B1 (ko) * 2005-10-21 2011-04-20 에프. 호프만-라 로슈 아게 폴리펩타이드의 재조합 발현 방법
CN101341252B (zh) 2005-10-28 2011-08-17 弗·哈夫曼-拉罗切有限公司 啮齿动物细胞中的蛋白质表达
JP5526332B2 (ja) * 2005-12-21 2014-06-18 シーエヌジェイ ホールディングス，インコーポレイテッド 組み換え法によって生物活性ビタミンｋ依存性タンパク質を製造する方法
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
US8354516B2 (en) 2006-05-17 2013-01-15 Hoffmann-La Roche Inc. Polypeptide producing cells
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
EP2035572A4 (de) 2006-06-30 2010-01-06 Univ Michigan Verfahren zur herstellung von faktor-viii-proteinen durch rekombinationsverfahren
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP1975228A1 (de) 2007-03-28 2008-10-01 Fachhochschule Mannheim Polynukleotide für verstärkte Expression eines relevanten Polynukleotids
CA2683423C (en) 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
JP5512514B2 (ja) * 2007-06-29 2014-06-04 エフ．ホフマン−ラ ロシュ アーゲー 改善された免疫グロブリンの産生をもたらす重鎖変異体
AU2008309934B2 (en) 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
EP2728017B1 (de) 2007-11-19 2016-08-24 Celera Corporation Lungenkrebsmarker und Verwendungen davon
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
SI2462237T1 (sl) 2009-08-06 2016-04-29 Cmc Icos Biologics, Inc. Postopki za izboljšanje ekspresije rekombinantnega proteina
ES2699718T3 (es) 2009-09-15 2019-02-12 Medlmmune Ltd Células para expresión transitoria y usos de las mismas
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
EP2339009A1 (de) 2009-12-22 2011-06-29 Sandoz Ag Kälteindusierbare Promotorsequenzen
AR081750A1 (es) 2010-03-31 2012-10-17 Boehringer Ingelheim Int Anticuerpos anti-cd40
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP3281954A1 (de) 2010-11-04 2018-02-14 Boehringer Ingelheim International GmbH Anti-il-23-antikörper
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
EP2753644A1 (de) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Breit neutralisierende vhh gegen hiv-1
CA2853531C (en) 2011-10-28 2020-03-10 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
MX347164B (es) 2011-11-16 2017-04-18 Boehringer Ingelheim Int Anticuerpos anti-il-36r.
BR112014014239B1 (pt) 2011-12-22 2021-10-13 F. Hoffmann-La Roche Ag Método para selecionar uma célula recombinante de mamífero transfectada estável, método para produzir um anticorpo e vetor de expressão
EP3816284A1 (de) 2011-12-22 2021-05-05 F. Hoffmann-La Roche AG Expressionsvektor für die rekombinante herstellung von antikörper in eukaryotischen zellen
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
WO2013119990A2 (en) 2012-02-10 2013-08-15 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
CN104254603A (zh) * 2012-02-14 2014-12-31 博尔托拉制药公司 用于制备xa因子抑制剂的重组解毒剂的方法
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US20150307863A1 (en) 2012-11-20 2015-10-29 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
AU2014248936B2 (en) 2013-03-12 2020-07-09 Cmc Icos Biologics, Inc. Improved recombinant protein expression using a hybrid CHEF1 promoter
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
RU2535871C1 (ru) * 2013-07-10 2014-12-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
MX367661B (es) 2014-01-31 2019-08-30 Boehringer Ingelheim Int Anticuerpos anti-baff novedosos.
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
CN114106146A (zh) 2015-02-06 2022-03-01 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
SG11201708399WA (en) 2015-04-14 2017-11-29 Boehringer Ingelheim Int Methods of treating diseases
AU2016262100B2 (en) 2015-05-12 2021-10-14 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3974451A3 (de) 2016-04-15 2022-07-06 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen erkrankungen
JP7050001B2 (ja) 2016-04-25 2022-04-07 シンティミューン，インコーポレイティド ヒト化親和性成熟抗ｆｃｒｎ抗体
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
AU2017259038B2 (en) 2016-05-02 2024-05-23 Prothena Biosciences Limited Antibodies recognizing Tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
US20180105588A1 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
AU2019206443A1 (en) 2018-01-10 2020-07-23 Cmc Icos Biologics, Inc. Bidirectional CHEFl vectors
CA3090321A1 (en) 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
WO2019235923A1 (en) 2018-06-04 2019-12-12 Erasmus University Medical Center Rotterdam Role for low density lipoprotein receptor-related protein 10 in progressive brain diseases
BR112020024078A2 (pt) 2018-06-29 2021-02-17 Boehringer Ingelheim International Gmbh anticorpos anti-cd40 para uso no tratamento de doença autoimune
CN110904127A (zh) 2018-09-18 2020-03-24 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US11208482B2 (en) 2018-11-26 2021-12-28 Forty Seven, Inc. Humanized antibodies against c-Kit
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
EP3935083A4 (de) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antikörper zur erkennung von tau
AU2020238676A1 (en) 2019-03-08 2021-09-16 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
CN114173809A (zh) 2019-04-02 2022-03-11 伊缪纯有限公司 免疫刺激组合物及其用途
US11267880B2 (en) 2019-05-09 2022-03-08 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
IL298431A (en) 2020-05-26 2023-01-01 Boehringer Ingelheim Int Anti-pd-1 antibodies
EP4288457A2 (de) 2021-02-05 2023-12-13 Boehringer Ingelheim International GmbH Anti-il1rap-antikörper
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CN114540352A (zh) * 2022-02-16 2022-05-27 艾瑞生命科学技术(常州)有限公司 一种多核苷酸、载体元件及表达载体和宿主细胞及应用
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
AU645294B2 (en) * 1989-12-22 1994-01-13 Merck Serono Sa Endogenous gene expression modification with regulatory element
US5650294A (en) * 1990-06-25 1997-07-22 Basf Aktiengesellschaft Isolated promoter and terminator of elongation factor 1-α
CA2092695A1 (en) * 1991-05-15 1992-11-16 Oliver Smithies Genomic modifications with homologous dna targeting
CA2051085C (en) * 1991-09-10 2001-08-21 Shigekazu Nagata Expression plasmids
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Also Published As

Publication number Publication date
RU2249617C2 (ru) 2005-04-10
PL331005A1 (en) 1999-06-21
SK285664B6 (sk) 2007-05-03
ATE318900T1 (de) 2006-03-15
HUP0004137A3 (en) 2003-08-28
EP0920498A1 (de) 1999-06-09
PL195604B1 (pl) 2007-10-31
HUP0004137A2 (en) 2001-03-28
NO990025D0 (no) 1999-01-04
CN101570753A (zh) 2009-11-04
CN1230991A (zh) 1999-10-06
RU2004136574A (ru) 2006-05-27
EP0920498B1 (de) 2006-03-01
NO990025L (no) 1999-03-01
ES2263206T3 (es) 2006-12-01
WO1998049289A1 (en) 1998-11-05
DE69833649D1 (de) 2006-04-27
IL127897A0 (en) 1999-11-30
BR9804896B1 (pt) 2013-11-26
US5888809A (en) 1999-03-30
IL127897A (en) 2005-12-18
BR9804896A (pt) 1999-08-31
CZ28099A3 (cs) 2000-02-16
DK0920498T3 (da) 2006-07-10
DE69833649T2 (de) 2006-12-28
SK11899A3 (en) 2000-05-16
AU7277098A (en) 1998-11-24
HU225764B1 (en) 2007-08-28
NO323853B1 (no) 2007-07-16
EP1676916A1 (de) 2006-07-05
CN100430477C (zh) 2008-11-05
CZ296544B6 (cs) 2006-04-12
AU742561B2 (en) 2002-01-03
JP2000513948A (ja) 2000-10-24
PT920498E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
HK1022719A1 (en) Hamster ef-1 alpha transcriptional regulatory DNA
TWI255854B (en) Baculovirus containing minimal CMV promoter
IL112873A (en) Rapamycin-fkbp12 binding proteins, their isolation and their use
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DE69433978D1 (de) Methode der spezifischen abschaltung von genen durch dna-methylierung
FR2680518B1 (de)
DE69130845T2 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
CA2259145A1 (en) Hamster ef-1.alpha. transcriptional regulatory dna
WO2000061729A3 (en) Regulation of the expression of transcriptional repressor genes using nucleic acid molecules
BR0010396A (pt) Composições e métodos para a modificação da expressão de genes
DK1235916T3 (da) Isolerede polynukleotider med et formindsket indhold af 5'CpG3' epigenitiske kontrolmotiver og anvendelser deraf
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU1447997A (en) Dna constructs and expression vectors derived from the adenovirus va rna i gene
WO2001047942A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180430